Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk, which is owned by Novo Holdings, will directly purchase the Bloomington location and two other fill-finish sites in Europe from its parent company. Catalent, a third-party manufacturer ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations on Wednesday. Here’s what you need to know ...

Novo Nordisk is buying three Catalent facilities for $11bn in a bid to resolve supply issues holding back growth of Ozempic for diabetes and obesity ... Brussels in Belgium, and Bloomington, ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

Novo Nordisk is not the only company that has realized the potential of the GLP-1 market, ... Agnani (Italy), Brussels (Belgium) and Bloomington (United States). Through this acquisition, ...

Ozempic maker Novo Nordisk NOVO.B-0.35%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases ...

Phil Powell, Indiana University professor of business economics, led off remarks on Wednesday with three statistics that he ...